Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 336 participants.

Also called NCT03151993

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 336 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03151993
Other papers using this trial's data
  • Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial The Lancet. Neurology, 2021-09 DOI, PubMed 34418399

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03151993. Randomized; no masking; primary purpose treatment. Start 2017-03-18 (actual); primary completion 2019-03-23 (actual). Results posted on 2025-04-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
Intervention (Drug)
Recombinant staphylokinase
Intervention (Drug)
Alteplase
Lead sponsor
Supergene, LLC (class: industry)

Record details

Record id
cardio:ct-nct03151993
Content hash
04f24494faf490097d3d4bb9099d8a87e08d5bf79b66d029c99739226c24e488